Pathogenesis of hepatic encephalopathy.
Hepatic encephalopathy is considered to be a reversible metabolic encephalopathy, which occurs as a complication of hepatocellular failure and is associated with increased portal-systemic shunting of gut-derived nitrogenous compounds. Its manifestations are most consistent with a global depression of CNS function, which could arise as a consequence of a net increase in inhibitory neurotransmission, due to an imbalance between the functional status of inhibitory (e.g., GABA) and excitatory (e.g., glutamate) neurotransmitter systems. In liver failure, factors that contribute to increased GABAergic tone include increased synaptic levels of GABA and increased brain levels of natural central benzodiazepine (BZ) receptor agonists. Ammonia, present in modestly elevated levels, may also augment GABAergic tone by direct interaction with the GABAA receptor, synergistic interactions with natural central BZ receptor agonists, and stimulation of astrocytic synthesis and release of neurosteroid agonists of the GABAA receptor. Thus, there is a rationale for therapies of HE that lower ammonia levels and incrementally reduce increased GABAergic tone towards the physiologic norm.
Department of Gastrointestinal and Liver Diseases, Academic Medical Center, Amsterdam, The Netherlands. E.A.Jones@AMC.UVA.NL
E A
EA
Jones
D000641:Ammonia / Q000378:metabolism; D018698:Glutamic Acid / Q000502:physiology; D006501:Hepatic Encephalopathy / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D017093:Liver Failure / Q000150:complications; D011963:Receptors, GABA-A / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D011963:Receptors, GABA-A; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D000641:Ammonia